PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

10 Customer Reviews

  • Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  •  

    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017.. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NX\EVXJlTnWwY4Tpc44hSXO|YYm= M2jBclI2KM7:TR?= MXyxJIg> MYricJVvfHNidHjlJGJc[V2SLXnu[JVk\WRiaX7jdoVie2ViaX6gdIhwe3Cqbz3DbIsyKGGwZDDwbI9{eGixLVXST{BmgHC{ZYPzbY9v NXuydG5XOjV5NkmxPFE>
MCF-7  MorKSpVv[3Srb36gRZN{[Xl? NG\pfI4yOCEQvF2= NXPzdo1YOSCq NHj1TW1qdmirYnn0d{BKVC1zOD3lcohidmOnZDDj[YxtKG2rZ4LheIlwdg>? M2PGfVI2PzJ5MEGx
HepG2  MX3GeY5kfGmxbjDBd5NigQ>? M4rYe|ExKM7:TR?= NYfsV4VtPSCq NFruU2NjdG:la4OgdIhwe3Cqb4L5cIF1\WRiTVHQT5MhcW6mdXPl[EBjgSCneH;n[Y5wfXNiVFfGMe6zOQ>? NFO2OJAzPTV4MES4PC=>
HepG2  NX61[2FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHhO2tNOjBizszN MlzONlQhcA>? NVvpZm95e3WycILld5NmeyCWR1[t{tIyNWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDDpcpZie2mxbh?= NFG5R2YzPTV4MES4PC=>
MDA-MB-231 M2jB[mZ2dmO2aX;uJGF{e2G7 MkWzNlUh|ryP MVeyMVMhcA>? MWHk[YNz\WG|ZYOgdE1GWktzL{KgZY5lKFNzMEDBOEBmgHC{ZYPzbY9v NH7BcW4zPTV3NUi3OS=>
SW480 MmTDSpVv[3Srb36gRZN{[Xl? Mn;wNlDDqM7:TR?= NWfXTI5COcLiaB?= NXLtTHhFemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[kBCXEZ|IIDyc5RmcW5? NIK1PGIzPTR2N{ixOi=>
HCT-15 NXO5fnIzTnWwY4Tpc44hSXO|YYm= M2DIdlEhcA>? MlPpZZR1\W63YYTld{BRT0V{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb:Kh NHPjU2szPTR|MUSyOS=>
HCT-15 M3HzdmFxd3C2b4Ppd{BCe3OjeR?= NWCy[4ZnOSCq MUXhZo9tcXOqZYOgeIhmKHC{b4TlZ5RqfmViZX\m[YN1eyCxZjDQS2UzyqCjZ3HpcpN1KGO3cnP1cYlvNWmwZIXj[YQh[XCxcITvd4l{ MUOyOVQ{OTR{NR?=
786-O M2jGW2Fxd3C2b4Ppd{BCe3OjeR?= MoHHOVDDqM7:TR?= NFnnXYMzPCCq M1;0fZBwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D NXrLZVBFOjR3MEi0O|Y>
A498 NEL3cnFCeG:ydH;zbZMhSXO|YYm= M{LSWlUxyqEQvF2= MX6yOEBp M1vyT5BwfGWwdHnheIV{yqC2aHWgdJJwNWGyb4D0c5Rq[yCnZn\lZ5R{KG:oIF7D NYLX[|M5OjR3MEi0O|Y>
NHBE NX[0PIJMTnWwY4Tpc44hSXO|YYm= NIDBZ4czNzJyIN88US=> MVuyJIg> NVHjdWdC[XS2ZX71ZZRmeyCLTD2zN{B{fGmvdXzheIVlKEO[Q1y4M2lNNThic3XjdoV1cW:w M{O1T|I1PDd7NUK2
A375 NEnheWhE\WyuIFnueoF{cW:wIFHzd4F6 M4fmO|Ex6oDVMkCgxtVO MUSyOEBp M1jDSpJm\HWlZYOgcYVt[W6xbXGgZ4VtdCCrbo\hd4lwdg>? M{fWNlI1PDZ4MEO2
HBMEC MVPGeY5kfGmxbjDBd5NigQ>? NG\hOYEyOCEQvF2= NGn0dVEyKGh? NYXtNFND[myxY3vzJHZGT0ZvaX7keYNm\CCHcHjBNkBmgHC{ZYPzbY9v NU\0c5gzOjR2NUi5PFI>
HPAEpiCs  NYPQV5E6TnWwY4Tpc44hSXO|YYm= MYizNEDPxE1? MYSxJIg> MofwbY5pcWKrdIOgWG5HNc7zIIP0bY12dGG2ZXSgdFQzN3B2NDDNRXBMKHCqb4PwbI9zgWyjdHnvci=> M3vFOFI1PDRzOEew
BeWo MlvjSpVv[3Srb36gRZN{[Xl? MXexNOKh|ryP NIT1dpYzKGh? MVfpcohq[mm2czDFVmsyNzJ? NX3Ie3U3OjR2M{O4OFY>
PC3  M3vVbmFxd3C2b4Ppd{BCe3OjeR?= MUe1NEDPxE1? NWD5eFJSOC53IHi= NYXBUWo6cW6qaXLpeJMhVUi\LUS0PU1qdmS3Y3XkJIFxd3C2b4Ppd:Kh MlzRNlQ1OjR6OEm=
HGC-27 M3HMNmFxd3C2b4Ppd{BCe3OjeR?= M4C3W|EhyrWP MXOxJIg> M37HeJN2eHC{ZYPz[ZMhWkGGMECxJJBtfXNiTVutNlIxPi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MYOyOFQyPjN2OR?=
MCF-7 MnTpSpVv[3Srb36gRZN{[Xl? MnjENVDDqM7:TR?= MVqxNE8{OCCvaX6= MojSdoVlfWOnczD0bIUhXVSSLXTldIVv\GWwdDDFVmsheGixc4Doc5J6dGG2aX;u M1u1UVI1OzlyOEG5
HUVECs MXXGeY5kfGmxbjDBd5NigQ>? MnTUNVDDqM7:TR?= NXfHfJRIOSCq MVrpcohq[mm2czD0bIUhUESOIILl[JVk\WRiQ1;YMVIh\XiycnXzd4lwdiCjbnSgVGdKNTJicnXs[YF{\Q>? MVGyOFM5PTFyOR?=
HeLa NUL1bYRMTnWwY4Tpc44hSXO|YYm= MYW1NEDPxE1? NWXRXG17OC53IHi= MYDicI9kc3NiVGLYMVEhdnWlbHXhdkBucWe{YYTpc44h[W6mIGTYUmlRKGSxd36tdoVofWyjdHnvci=> NWn0[JVvOjR|N{[4Nlc>
HL-60  NFTxdGdHfW6ldHnvckBCe3OjeR?= M371elExNzJyIN88US=> M4PuUVEhcA>? NFyyNI1qdmirYnn0d{B1cGYEoF6uJINpcW6nboPpd4V5fHKjY4VCpIlv\HWlZXSg[Iln\mW{ZX70bYF1cW:wIHnueI8h\3KjboXsc4N6fGW| NWTGTJNGOjR|NUewNlA>
HL-60 MmOySpVv[3Srb36gRZN{[Xl? NGnocXUzKML3TR?= MWSxOkBp MoGwSG1UVw>? M2PLUolvcGmkaYTzJJRp\SCjc4PvZ4lifGmxbjDv[kBxWzZ{MTDSZYYuOSCjbnSgUmZCXGN|LDDhcoQhfGinIGLBMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJI52[2ynYYKgUmZCXGN| NF[1bYszPDN|MEC2PC=>
HEK 293 NILKW4JHfW6ldHnvckBCe3OjeR?= NXHjWZFrOTBizszN M{\nR|UhcA>? NIDjSZJFVVOR NWraR4tRcW6qaXLpeJMhX262LXnu[JVk\WRizsKtZ4F1\W6rbj;UR2Y1KGGldHn2bZR6KGGwZDDueYNt\WG{IN8yMYNifGWwaX6gZYNkfW23bHH0bY9v MYeyOFMzPDN4Nh?=
HEK 293 Ml3DSpVv[3Srb36gRZN{[Xl? NUfQV2g4OTBizszN MkLVOUBp MnLhSG1UVw>? M1:5NJN2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> MUOyOFMzPDN4Nh?=
SW480 M1nnNmZ2dmO2aX;uJGF{e2G7 NFzCcIYyOCEQvF2= NGWwO2kzOCCq M3XrXGROW09? Mkfid5VxeHKnc4Pld{B1cGViQ2LUJIFkfGm4aYT5 NFi5[VEzPDN{NEO2Oi=>
HCSMCs M3mxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNEDPxE1? Mn3TNlQhcA>? NX3ofYw{[myxY3vzJGZCSlB2LXnu[JVk\WRiSFPBV21EKHC{b3zp[oVz[XSrb36= NITzepAzPDNzMkO4NS=>
PANC-1 MV7GeY5kfGmxbjDBd5NigQ>? MX6yNEDPxE1? MXm0PEBp M2Gw[IlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJO6VPkRiaX6gdoV{eG:wc3WgeI8hfGinIGDQRXLPvMLiYXfvcol{fMLi NV\kSIlpOjR{OUSxN|M>
A549 MYDGeY5kfGmxbjDBd5NigQ>? NX3HVWRnOzBizszN M2jvO|AvPSCq NV\yTFZSTE2VTx?= MnfpbY5pcWKrdIOgeIhmKHSqcn;tZolvNWmwZIXj[YQhUUxvOD;DXGNNQC2OdXOgZYN1cX[rdIm= Ml\nNlQzPzd4OU[=
A549 NGe3VpZHfW6ldHnvckBCe3OjeR?= Mn;hN|Ah|ryP NUTlV5NwOC53IHi= MnexSG1UVw>? MYXpcohq[mm2czD0bJJwdWKrbj3pcoR2[2WmIFOvSWJR|rJiVHjyNlM2yqCyaH;zdIhwenmuYYTpc44> MXKyOFI4PzZ7Nh?=
MC-3 MYjBdI9xfG:|aYOgRZN{[Xl? NEfsflcyOCEQvF2= NVjXZWhnOjRiaB?= MkTndI91\W62aXH0[YQhVUWVQz3pcoR2[2WmIHHwc5B1d3OrczDpckAh[2WubIO= MkftNlQzPzB3MkO=
Raji  NYPzV4ZDTnWwY4Tpc44hSXO|YYm= M{HwTFExKM7:TR?= NXzyRWI5OSCq M2fUR4Jtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM|IheGixc4Doc5J6dGG2aX;u MkG5NlQzPjl4M{C=
Raji  M3myRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7uOYkyOCEQvF2= M37iXVEhcA>? MVXpcohq[mm2czD0bIUh[mG|YXygc5IhcHOEQV\GMZN1cW23bHH0[YQh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdIm= MUCyOFI3QTZ|MB?=
HT29 NXTifVdQTnWwY4Tpc44hSXO|YYm= Mni5NVAh|ryP MYGyJIg> NXm0UHZNcW6qaXLpeJMhd2ZiSlHLNkwhTVKNMT:yJIFv\CCVVFHUN{BxcG:|cHjvdplt[XSrb36= NGrySYUzPDJ4NUK5Ny=>
HepG2 MoeyRZBweHSxc3nzJGF{e2G7 M{fmSVIxKM7:TR?= NFXlT|gzPCCq NV3zR2hxcW6qaXLpeJMhTVKNMT:yJJBpd3OyaH;yfYxifGmxbjDhcoQh\W6qYX7j[ZMhXkJzLXnu[JVk\WRiYYDvdJRwe2m| NW\PfpU6OjR{NEe5NFk>
HepG2 MYfGeY5kfGmxbjDBd5NigQ>? MUGyNEDPxE1? NHjiVFQzKGh? M1nFWYVvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= M1mzOlI1OjR5OUC5
TE4 Mmq1SpVv[3Srb36gRZN{[Xl? MYGyNE82OC9zMECg{txO MV[0PEBp NGPSUpJFVVOR MlPhbY5pcWKrdIOgdE1GemtiYX7kJJdwenSvYX7ubY4h\G:5boLl[5Vt[XSnZDDwMWFsfCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnHONlQzPDRyMkO=
TE1 NIr3UHhHfW6ldHnvckBCe3OjeR?= M2P0dFIxNzVyL{GwNEDPxE1? MVS0PEBp M4HTOGROW09? M2S5dYlvcGmkaYTzJJAuTXKtIHHu[EB4d3K2bXHucolvKGSxd37y[Yd2dGG2ZXSgdE1Cc3RiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEnYXYozPDJ2NECyNy=>
KYSE30 NEGx[YtHfW6ldHnvckBCe3OjeR?= M3TSOVIxNzVyL{GwNEDPxE1? MWW0PEBp NEDKUWlFVVOR MYDpcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUOyOFI1PDB{Mx?=
TE1 M2LoT2Z2dmO2aX;uJGF{e2G7 Mn7XOVAh|ryP NYDWV3M{PDhiaB?= NUC1U4dETE2VTx?= Ml3aeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MYWyOFI1PDB{Mx?=
TE3 MYXGeY5kfGmxbjDBd5NigQ>? MWS1NEDPxE1? MXi0PEBp MVTEUXNQ NGjxXWN2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= NHXVNpgzPDJ2NECyNy=>
TE4 M{ntSGZ2dmO2aX;uJGF{e2G7 NGjGeIc2OCEQvF2= MWC0PEBp MVHEUXNQ NHjPdJl2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= MUWyOFI1PDB{Mx?=
TE5 M1j2WGZ2dmO2aX;uJGF{e2G7 NGP0dmk2OCEQvF2= M{LsVVQ5KGh? NHPK[nFFVVOR MVT1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? NGXSUVEzPDJ2NECyNy=>
KYSE30 NGPnTIVHfW6ldHnvckBCe3OjeR?= MX61NEDPxE1? MmSwOFghcA>? NYexZ5FQTE2VTx?= MWH1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBJVEFiY3zhd5MhUQ>? MlTzNlQzPDRyMkO=
MKN7 MYHGeY5kfGmxbjDBd5NigQ>? M1;IRlUxKM7:TR?= M3fSblQ5KGh? NXfkUXZnTE2VTx?= MXHpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| MXSyOFI1PDB{Mx?=
OE19 NWTxNllpTnWwY4Tpc44hSXO|YYm= MVe1NEDPxE1? MlvmOFghcA>? MkmxSG1UVw>? M1LkbYlv[3KnYYPld{BmgHC{ZYPzbY9vKG:oIFjMRU1CODJib4KgTGxCNUF{NDDtc4xm[3WuZYO= MnjaNlQzPDRyMkO=
KATOIII  NIXGT2lHfW6ldHnvckBCe3OjeR?= M4\BPFUxKM7:TR?= NUTLN3BVPDhiaB?= M4HuTGROW09? NEXjbXNqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz MWGyOFI1PDB{Mx?=
NCI-N87  MUHGeY5kfGmxbjDBd5NigQ>? M1rvT|UxKM7:TR?= NX;1dIRHPDhiaB?= MmHDSG1UVw>? NXrrXlRIcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> M2PhcFI1OjR2MEKz
NUGC3 NYTDTHJmTnWwY4Tpc44hSXO|YYm= MlTwOVAh|ryP MVm0PEBp MXfEUXNQ Mn3ObY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZiSFzBMWExOiCxcjDIUGEuSTJ2IH3vcIVkfWyncx?= NGfFc2kzPDJ2NECyNy=>
NUGC2 MXLGeY5kfGmxbjDBd5NigQ>? MVK1NEDPxE1? M{K2O|Q5KGh? MknZSG1UVw>? NF3rT|JqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz MUKyOFI1PDB{Mx?=
SGC-7901  M{TLXmFxd3C2b4Ppd{BCe3OjeR?= Ml3NNlAh|ryP NEKxNYszPCCq NGT0V5RqdmirYnn0d{BEWC2vZXTpZZRm\CCjcH;weI9{cXN? NVLWd4N5OjR{NEGzOVE>
MG-63 M{THRmZ2dmO2aX;uJGF{e2G7 NXHRS2NWOjBizszN Mor4NE42KGh? M3f5UYJtd2OtczD0bIUhS0hvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBGVEtzIIDyc5RmcW5iZYjwdoV{e2mxbh?= Mm\TNlQzOzl4NEC=
ARPE-19 NVTHeoY5TnWwY4Tpc44hSXO|YYm= NWTvU|V[OjBizszN NF[wWlcxNjViaB?= MkLCbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0 NH\CUZEzPDJ{N{mxPC=>
CRL-2302 NEjUNVlHfW6ldHnvckBCe3OjeR?= NXnwRYl3OjBizszN MYKwMlUhcA>? M4e5N4lvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> MnHSNlQzOjd7MUi=
MCF-7 M3\6XGZ2dmO2aX;uJGF{e2G7 NWP4VZNHOjBizszN MkTWNUBp NFfNeoVi[m:uaYPo[ZMh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUlugZ48ufHKnYYTt[Y51KHerdHigZ49vcnWpYYTl NW\SfXd7OjR{MU[yPFk>
MCF-7 NWHJTG93SXCxcITvd4l{KEG|c3H5 Ml\lNlAh|ryP MmW2NUBp MnjkbY5kemWjc3XzJINie3Cjc3WtPUBmdnq7bXWgZYN1cX[rdIm= NH;Y[4wzPDJzNkK4PS=>
DLD-1  M3T6OWZ2dmO2aX;uJGF{e2G7 NXO1UlV7OjEEoN88US=> MnzGOFghcA>? MmXXdoVlfWOnczD0bIUhSk6LUEOg[ZhxemW|c3nvckBxemVvdILlZZRm\CC5aYToJFUu[XqjLXTD MXmyOFIyOTV6MR?=
HT-29 NIe5TlZHfW6ldHnvckBCe3OjeR?= NYHPZ5dqOjEEoN88US=> NFz3T3I1QCCq M2PBT5Jm\HWlZYOgeIhmKEKQSWCzJIV5eHKnc4Ppc44heHKnLYTy[YF1\WRid3n0bEA2NWG8YT3kRy=> M1f6SVI1OjFzNUix
7402 NVPnWoZ7SXCxcITvd4l{KEG|c3H5 NVPPNIRoOzBizszN MYO1JIQ> M3LNXIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M4TkVlI1OjFzMkWz
7721 M2DBN2Fxd3C2b4Ppd{BCe3OjeR?= MVmzNEDPxE1? Mn3OOUBl NWXzd3Zj\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>? MYSyOFIyOTJ3Mx?=
SGC7901  M{nUZ2Fxd3C2b4Ppd{BCe3OjeR?= M3H3OFUxyqEQvF2= NHzlSmkzPC92OD:3NkBp NWPXfJl6TE2VTx?= NIrubWdqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFrBT|Ihe2iUTlG= NEjYO3MzPDF5OEK0NC=>
SMMC7721 M4GxcWZ2dmO2aX;uJGF{e2G7 NGm0V48zPS93MDFOwG0> MWCyOEBp MUnzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSWu2IH;yJJAuTVKNMT:yxsA> MVOyOFE3QDB3Nh?=
MCF-7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DBVlExKM7:TR?= MU[0PIg> NV\CN4x[TE2VTx?= NV;ObnYyemW4ZYLz[ZMhSk6ILXnu[JVk\WRiY3XscEBkgWOuZTDhdpJme3R? NVfC[2xVOjRzNkO0NFQ>
Caco-2 M3mxeGZ2dmO2aX;uJGF{e2G7 NUOxb49kPTEEoN88US=> Ml7wOFhp MnX3SG1UVw>? MkDQ[Y5p[W6lZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBUS06QMVGsSnh[TDNuwrDMR3QtyqCOT2isxsBJUUZ|QT|CpHpIOTZuwrDQSGU3ScLiYX7kxsBNT0GOU{G2xsBo\W6nc9MgZ48ufHKnYYTl[EB4cXSqIFTlfC=> MVuyOFE3OTZ7NR?=
HAECs MYnGeY5kfGmxbjDBd5NigQ>? NXjMbYdXOTBizszN NITa[pMyKGh? M{S5RuKh[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCLQ1HNMVEh[W6mIG\DRW0uOSCneIDy[ZN{cW:w M1yxSFI1OTN2NkW3
Ca9-22 M3m3e2Z2dmO2aX;uJGF{e2G7 M1\hfVMh|ryP MoLuNUBp NEPPeGZi[m:uaYPo[ZMhfGinIHHibYxqfHlib3[gTIJTKHSxIHnu[JVk\SCLTD24JJBzd2S3Y4Tpc44> NHPVe3UzPDF{NkWzNi=>
Ca9-22 M{CyXWZ2dmO2aX;uJGF{e2G7 MVKzJO69VQ>? NEPP[4IyNzJiaB?= MYjy[YR2[2W|IFjiVk1qdmS3Y3XkJGFVTi1{IIDoc5NxcG:{eXzheIlwdg>? NXrSWYo5OjRzMk[1N|I>
AGS M1j3XmZ2dmO2aX;uJGF{e2G7 MX6xNEDPxE4EoB?= NYDn[Gd6OC53IHi= M{P3colvcGmkaYTzJJRp\SC3cILl[5Vt[XSrb36gc4YhfGinIFnMMVgh\2WwZR?= MkfqNlQyODZzNk[=
Caco-2  NWHpTWJ6SXCxcITvd4l{KEG|c3H5 Mnu5NVDDqM7:TR?= Mki4NlTDqGh? MYPk[YNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTC1MWZW NX\Zd5ZpOjRyOUW4OlM>
HCT-8 NHzadm9CeG:ydH;zbZMhSXO|YYm= NITRS|IyOMLizszN NXH2NYx4OjUEoHi= MnzC[IVkemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgOU1HXQ>? M1\yWFI1ODl3OE[z
A549 NFvafGlHfW6ldHnvckBCe3OjeR?= MWq1NOKh|ryP MWGyJIg> Mnj1Zoxw[2u|IFXST{BxcG:|cHjvdplt[XSrb36gcYVlcWG2ZXSgZpkhOSx{LV7R NEf2fmczPDB4N{eyOy=>
HPMC MoDNSpVv[3Srb36gRZN{[Xl? MmmxNVDDqM7:TR?= MX20PEBp M3;tXZJmfmW{c3XzJJRp\SClaHHu[4V{KGmwIHPlcIwhdW:{cHjvcI9ogSCrbnT1Z4VlKGK7IFjHVGRU NGThVZUzPDB2MkizPC=>
HPMC MmHHRZBweHSxc3nzJGF{e2G7 NEf1UnAyOMLizszN NXjQUFJbOjUEoHi= NWHpR49LemW4ZYLz[ZMh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKR2DEVy=> NV2yT3BPOjRyNEK4N|g>
MGC803  NUX3T3IySXCxcITvd4l{KEG|c3H5 M3X6flIxyqEQvF2= NXq1Rlh1OSCq NYjTOHptcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliSV\OMe6yyqCjbnSgOgKBui2GRmXS Ml3UNlQxOjd5NUC=
SGC7901 MoTMRZBweHSxc3nzJGF{e2G7 M4Czb|IxyqEQvF2= M2\i[lEhcA>? NHPEOW5qdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK= NUPLRW9mOjRyMke3OVA>
COLO205 M2[xemFxd3C2b4Ppd{BCe3OjeR?= NWG3O3BDOTBxMkCvOFAh|ryP MXSyOEBp Mnr5bY5lfWOnczDEUmEhdGGmZHXyJIZwem2jdHnvci=> MVGyOFAyQTFyOB?=
G292  NGfXO|FCeG:ydH;zbZMhSXO|YYm= M4HBc|MxyqEQvF2= M3PublIhcA>? NUjoT4V[emW|dH;y[ZMh[2Gyc3HpZ4lvNWmwZIXj[YQh[2WubDDk[YF1cA>? NWLyeZZwOjRyMUK5N|A>
BxPC-3 MnjNSpVv[3Srb36gRZN{[Xl? M{j0SlExKM7:TdMg MXO2JIg> MVvpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36= M1Hx[VI{QTd|N{Gw
HPAF-II Ml\pSpVv[3Srb36gRZN{[Xl? MYOxNEDPxE4EoB?= MYC2JIg> MYHpcoNz\WG|ZTDtbXIuOTR|IHX4dJJme3Orb36= NYL0c49zOjN7N{O3NVA>
HL-60 NHzOW|RCeG:ydH;zbZMhSXO|YYm= MXi1NOKh|ryP NVWwWZhEOSCq MVLy[ZNkfWW|IFLBNVQ2KG2nZHnheIVlKGGyb4D0c5Nqew>? NG\KRmgzOzl2OEe1NS=>
HepG2 MXHGeY5kfGmxbjDBd5NigQ>? MlXoOFAh|ryP MVy2M|EzKGh? Mk\MbY5pcWKrdIOgeIhmKGmwY4LlZZNmKG:oIICtSXJMOSCjbnSgdE1kNUq3bjDwdo91\WmwIHX4dJJme3Orb36gZpkhWEx? NITmVogzOzl2Mki1NS=>
HUVECs NEfYRYdHfW6ldHnvckBCe3OjeR?= MUKyOUDPxE1? M1y2clEhcA>? NH7GUYhqdmO{ZXHz[UBPTi4QulKgdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbh?= NFHGUm0zOzlyMUCwPC=>
LNCaP  MmixSpVv[3Srb36gRZN{[Xl? MnfYNVAh|ryPwrC= NX3VPXdvOSCq Mo[0[IVkemWjc3XzJJRp\SCHR1[geZBz\We3bHH0[YQheC2\Qj2x NXXMd5FMOjN6M{izNVg>
HL60  MnTQSpVv[3Srb36gRZN{[Xl? MUiyNOKh|ryP MojMO|IhcA>? M4\X[GROW09? MUPpcohq[mm2czDkZZNifGmwaXKtbY5lfWOnZDDDSFEy[iCneIDy[ZN{cW:w NXm0T|R4OjN6MkW1PFU>
NB4  MU\GeY5kfGmxbjDBd5NigQ>? M{f6VlExKM7:TdMg NW\tenBmPzJiaB?= MmrsSG1UVw>? MnXzbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= M3HXd|I{QDJ3NUi1
EPOR/CR3 NUjqepdZTnWwY4Tpc44hSXO|YYm= NEHlcYY2OMLizszN NY\NPXJQOyCq NX;2cVNLemWmdXPld{BGWE9iYX7kM49zKEmOLUOtbY5lfWOnZDD0bIUhfHm{b4PpcoUheGixc4Doc5J6dGG2aX;uxsA> NU\HflJiOjN6MkC3N|E>
HUASMCs Mm\ISpVv[3Srb36gRZN{[Xl? NEHQXXAyOCEQvF5CpC=> MoezNlQhcA>? NEDmPHBlcW2rbnnzbIV{KEGwZzDJTU1k[XW|ZXSgV29EWzNibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wwrC= NYjh[GhxOjN6MU[0Olg>
HUASMCs MVvGeY5kfGmxbjDBd5NigQ>? NHzTNZYyOCEQvF5CpC=> NIPMOVMzPCCq NIrJcnlqdmirYnn0d{BCdmdiSVmtbY5lfWOnZDDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGyndnXs M2LScVI{QDF4NE[4
SGC7901 NXGweGpuTnWwY4Tpc44hSXO|YYm= NGXmTFAyOCEQvF5CpC=> NFiweW8zPCCq MYTpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I> NIPmdVQzOzd7MkW4PC=>
MKN45 NWX5eXNxTnWwY4Tpc44hSXO|YYm= MnvUNVAh|ryPwrC= MYWyOEBp NH\PO2dqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxcG:|cHjvdplt[XSnZDDFVmsyNzJ? MkfhNlM4QTJ3OEi=
SGC7901 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jJ[|ExKM7:TdMg Mkf4NlQwPDhxN{KgbC=> NFTYe2VqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= Mlq1NlM4QTJ3OEi=
MKN45 M2r1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToNVAh|ryPwrC= NGnpbY4zPC92OD:3NkBp M1P3Z4lvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW NUmwfnZTOjN5OUK1PFg>
SGC7901 MoDHRZBweHSxc3nzJGF{e2G7 MkX0NVAh|ryPwrC= M4r6SlI1KGh? MnO3bY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? MVGyN|c6OjV6OB?=
MKN45 NUDjfpQ2SXCxcITvd4l{KEG|c3H5 NYTsT5BKOTBizszNxsA> NVnZNGY3OjRiaB?= Mni5bY5kemWjc3XzJJRp\SCGQWDUMYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? M1TPUlI{Pzl{NUi4
BxPC-3 cells M3PFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\qNlDDqM7:TR?= NEL5[nYxNjViaB?= M4rvfIlvcGmkaYTzJHZGT0ZvQT3y[Yd2dGG2ZXSgTHVXTUNiZ4Lve5RpKGGwZDD0eYJmKG[xcn3heIlwdiCrbnT1Z4VlKGK7IGDBVk0zKEGS NFnSO2IzOzd4NEC0Oi=>
NB4  MV;BdI9xfG:|aYOgRZN{[Xl? MmrJNVAwOjBxNkCg{txO NH3CfYwyNjViaB?= M1u3RmROW09? NHnSR4Rl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTl[EB4cXSqIGDhZ4xqfGG6ZXy= M3TWWVI{PzN3NUSx
HepG2  Mn6ySpVv[3Srb36gRZN{[Xl? MXqyNOKh|ryP NGTrOGEzPCCq M3zm[IlvcGmkaYTzJJRp\SCKTz2xJJBzd3SnaX6g[ZhxemW|c3nvckBkdy22cnXheIVlKHerdHigcYV1\m:{bXnu NXvTSVJCOjN5MEe2NFk>
HUVECs Mlq4RZBweHSxc3nzJGF{e2G7 M3fVTFIwPCEQvF2= NWDHc|lEOjRxNEigbC=> MYTpcoR2[2W|IHPlcIwh\GWjdHi= NXzQdnlGOjN5MEe1NlA>
KG-1  M2TzdWFxd3C2b4Ppd{BCe3OjeR?= NVjBTWtUOjEEoN88US=> MnHsNVIhcA>? NVLJOFND\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBUOQ>? NU\J[phYOjN5ME[2PVE>
AML 1# NUPDUo1ESXCxcITvd4l{KEG|c3H5 MoS2NlDDqM7:TR?= M2LTV|EzKGh? NH;tV4FmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JHMy M1n6T|I{PzB4Nkmx
A2780  NIjWTnBHfW6ldHnvckBCe3OjeR?= MnT3NlDDqM7:TR?= NVTLXYJbOSCq MlW0Zoxw[2u|IFTUR2QucW6mdXPl[EBFWjViZYjwdoV{e2mxbh?= M2S2c|I{Pjl4OE[y

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID